Micron Technology, Inc. vs Smith & Nephew plc — how do they compare? Micron Technology, Inc. trades at $1,029 (market cap $1.17T), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Micron Technology, Inc. is far larger — about 105.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Smith & Nephew plc for 121 Days on average.
| MU | SNN | |
|---|---|---|
Market Cap | $1.17T | $11.10B |
Volume | 29,425,906 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $1.21K | $37.17 |
52-Week Low | $181.60 | $26.42 |
Typical Hold Time | 48 Days | 121 Days |
Enterprise Value | $1.13T | $14.13B |
Dividend Yield | 0.06% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,029, down 5.42% over the past session, despite strong fundamental performance. The stock shows bullish technical signals with robust earnings beats in recent quarters (Q2 2026 EPS of $33.42 vs. $31.77 expected) and exceptional profitability metrics, including a 63.8% net income margin. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus strongly bullish (82.85% buy ratings) and a $1,590 price target, though risks include cyclical memory pricing and potential AI demand normalization. The company's strong cash flow generation ($17.53B operating cash flow in 2025) and expanding margins support continued upside potential for long-term investors.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →